Mesoblast share price surges 11% following horror start to August

Mesoblast's gains today will certainly come as welcome news to bruised shareholders.

| More on:
A man in a business suit wearing boxing gloves slumps in the corner of a boxing ring representing the beaten-up Zip share price in recent times

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price is taking off today.

This will certainly come as welcome news to those bruised shareholders who've held onto the stock during what's been an absolute horror start to the month.

In what looks set to mark the first day of gains for the stock since 19 July, shares in the ASX biotech company are up 11.4% in late morning trade, at 39 cents apiece.

As you can see in the chart above, calling this a horror month is no hyperbole. Even with today's intraday gains factored in the Mesoblast share price is down 66% in August. And investors who bought the stock near market close on 19 July will be nursing losses of 71%.

Ouch!

What's gone so wrong for the Mesoblast share price?

Mesoblast was among 2023's standout performers for the first seven months of the year. Shares were up an impressive 59% year to date when the closing bell rang on 19 July.

The stock then began to slip, and really got into trouble last Friday, 4 August.

That's when Mesoblast exited a trading halt with a very unwelcome announcement.

The company has been attempting to gain United States Food and Drug Administration (FDA) approval for its stem cell therapy, remestemcel-L, for a number of years.

On Friday, investors learned that the FDA was not ready to give the green light for the use of Mesoblast's treatment in the world's top economy, saying it needed more data.

Management said they would press ahead to gain that approval, but investors reacted by sending the Mesoblast share price down 56.9% on the day.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »